Does High Blood Sugar Affect CAR-T Outcomes in Multiple Myeloma? | IMS 2026

Does High Blood Sugar Affect CAR-T Outcomes in Multiple Myeloma? | IMS 2026
PERSEUS 6-Year Results: D-VRd Improves Myeloma PFS & Supports Dual Maintenance | IMS 2026
Multiple Myeloma Q&A: CAR-T, Bispecifics, IVIG, Bone Health, Genetics and Relapse
CMV Reactivation After CAR-T: Who Is at Risk? | IMS 2026
Supplements in Myeloma, MGUS & SMM: HealthTree Survey Results & Future Research | IMS 2026
Mass Spectrometry in Myeloma: Can a Blood Test Reduce Bone Marrow Biopsies? | IMS 2026
Does Tec-Dara Help Myeloma Patients Live Longer? | IMS 2026
Staying Strong During Treatment: Fatigue, Infections & Bone Pain | Kate Mimken, FNP-C
Can Resistance Exercise Help Heal Bone Lesions in Multiple Myeloma? | IMS 2026
Can CD4/CD8 T-Cell Ratio Predict Parkinson-Like Side Effects After BCMA CAR-T in Myeloma | IMS 2026
Can Iberdomide Replace Revlimid in Newly Diagnosed Myeloma? KId Results | IMS 2026
MajesTEC-3: Could Teclistamab + Daratumumab Lead to a “Functional Cure” in Myeloma? | IMS 2026
Redefining What's Possible: The Future of Myeloma Therapy in 2027 | Jeff Matous, MD
Top 5 Things Newly Diagnosed Multiple Myeloma Patients Should Know | IMS 2026
MajesTEC-5: High MRD-Negative Rates With Talquetamab Combo in Newly Diagnosed Myeloma | IMS 2026
Social Security Disability and Supplemental Income Benefits | Dollars & Diagnosis
CARTITUDE-2: Can Earlier Cilta-Cel CAR-T Lead to Long-Term Remission or Cure in Myeloma? | IMS 2026
Infection Prevention in Multiple Myeloma: What Patients Need to Know | IMS 2026